Trastuzumab Deruxtecan in Advanced Breast Cancer

计划入组 118 人 · 首次发布于 2025 年 9 月 18 日

Medical Access Program for Patritumab Deruxtecan

首次发布于 2023 年 10 月 25 日

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

计划入组 140 人 · 首次发布于 2025 年 5 月 1 日

Raludotatug deruxtecan

Datopotamab deruxtecan(Datroway)

Ifinatamab deruxtecan

Patritumab Deruxtecan Shows PFS Improvement in EGFR-Mutated NSCLC

FDA Accepts Datopotamab Deruxtecan BLA for Nonsquamous NSCLC Treatment

Datopotamab Deruxtecan Shows Promise in Advanced Non-Small Cell Lung Cancer